Clinical trials: Alcohol Related Disorders
Alcoholic Liver Cirrhosis
Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis
This study will evaluate the safety and efficacy of mesenchymal stem cells in patients with cirrhosis of liver. Stem cells will be injected into the hepatic artery. Improvement in various parameters will be observed over 2 years.
- Trial name
- NCT01591200
- Testing
- Allogeneic Mesenchymal Stem Cells
- Where
- 10 sites in India
- Volunteers
- 40 people
- Sponsor
- Stempeutics Research Pvt Ltd
Alcohol Dependence, Alcohol Interaction
Clinical Trial to Evaluate the Safety of PT150 (Formerly ORG34517) When it is Taken Concurrently With Alcohol
The purpose of the clinical study is to compare pharmacodynamic and safety endpoints following an alcohol challenge prior to and concurrent with PT150 (study drug) treatment.
- Trial name
- NCT03548714
- Testing
- PT150, Beverage
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pop Test Oncology LLC
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Alcohol Dependence
ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
This study will evaluate the safety and efficacy of ALKS33 (RDC-0313) compared with placebo in adults with alcohol dependence. There will be 11 study visits conducted over a period of about 4 months.
- Trial name
- NCT00981617
- Testing
- ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg)
- Where
- 27 sites in United States
- Volunteers
- 406 people
- Sponsor
- Alkermes, Inc.
Alcoholic Liver Cirrhosis
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.
- Trial name
- NCT03838250
- Testing
- Cellgram™ (Bone marrow-derived MSCs)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pharmicell Co., Ltd.
Alcoholic Hepatitis
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe…
- Trial name
- AH (NCT03432260)
- Testing
- DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Durect
Alcohol Use Disorder
Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare
This is an exempt, retrospective study of a limited set of information obtained from patients' medical records at 10 to 12 substance abuse treatment programs combined with alcohol breath analyzer results during up to 3 years of…
- Trial name
- NCT02544581
- Testing
- Soberlink combined with aftercare services
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- SoberLink, LLC
Alcohol Dependence
A Study for the Treatment of Alcohol Dependence
The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence.
- Trial name
- NCT00804570
- Testing
- LY2196044
- Where
- 17 sites in United States
- Volunteers
- 375 people
- Sponsor
- Eli Lilly and Company
Acute Alcohol Intoxication
Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication
This will be a (2 visit) double-blind, randomized, placebo crossover design clinical study to assess the potential benefits of FSD-F2R6-A-CP versus a placebo by assessing its impact on side effect profiles as well as cognitive…
- Trial name
- METAL-2 (NCT06505239)
- Testing
- FSD-F2R6-A-CP
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Quantum Biopharma
Substance Abuse
Substance Treatment and HIV Testing and Referral System
The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs.
- Trial name
- STaRS (NCT01488630)
- Testing
- STaRS
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Alcohol Dependence
Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence
The purpose of this study was to assess efficacy and safety of the study drug Odelepran, 125 mg as compared to placebo in the treatment of alcohol dependence in adult outpatients.
- Trial name
- NCT03663374
- Testing
- Odelepan
- Where
- 22 sites in Kazakhstan, Russia
- Volunteers
- 644 people
- Sponsor
- R-Pharm
Alcohol Dependence
Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients
The purpose of the study is to assess the efficacy of Xylka® (baclofen) compared to placebo on continuous abstinence rate during 20 weeks of treatment, after withdrawal, in alcohol dependent patients receiving Brenda therapy…
- Trial name
- ALPADIR (NCT01738282)
- Testing
- Baclofen
- Where
- 38 sites in France
- Volunteers
- 316 people
- Sponsor
- Ethypharm
Alcohol Use Disorder, Post Traumatic Stress Disorder
CCTAP: Cognitive Control Training for Treatment of AUD-PTSD
The primary objective of this study is to evaluate the feasibility of the revised brain training program with individuals diagnosed with Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT03200028
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Posit Science Corporation
Alcohol Dependence
A Study in the Treatment of Alcohol Dependence.
H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management.
- Trial name
- NCT00805441
- Testing
- LY686017
- Where
- 21 sites in United States
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Substance Use Disorders, Alcohol Use Disorders
DEVELOPMENT OF A NOVEL PEER RECOVERY SUPPORTER TRAINING PLATFORM
This study tests an online training platform for peer recovery support specialists, people in recovery who support others with alcohol and other substance use problems.
- Conditions
- Substance Use Disorders, Alcohol Use Disorders, Recovery Support Services, Peer Recovery Coaching
- Trial name
- NCT07044531
- Testing
- Training-as-Usual (TAU), TDPP-A (Asynchronous Platform), TDPP-Z (Hybrid)
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Thrive Digital Health, LLC
Alcoholic Hepatitis
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
- Trial name
- AH (NCT01912404)
- Testing
- IDN-6556
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Alcohol Use Disorder
Acamprosate Initiated During Alcohol Detoxification
Acamprosate is approved by the Food and Drug Administration (FDA) for the treatment of alcoholism. The purpose of this study is to see if initiating acamprosate early in alcohol detoxification instead of waiting until…
- Trial name
- NCT00360594
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Forest Laboratories
Alcohol Use Disorder
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
This study is aimed at examining whether GET73 modulates the indices of central glutamate and γ-aminobutyric acid (GABA) levels in recently abstinent subjects that meet Alcohol Use Disorder (AUD) criteria, as measured by proton…
- Trial name
- NCT03418623
- Testing
- GET73
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Alcohol Dependence
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.
- Trial name
- NCT02197598
- Testing
- nalmefene
- Where
- 3 sites in Germany
- Volunteers
- 45 people
- Sponsor
- H. Lundbeck A/S
Alcoholism
Study of Aripiprazole in Subjects With Alcoholism
The purpose of this clinical research study is to learn whether subjects treated with aripiprazole are able to abstain from alcohol use for a greater number of days than subjects treated with placebo.
- Trial name
- NCT00082199
- Testing
- Aripiprazole
- Where
- 14 sites in United States
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.